Arecor appoints Sarah Howell COO
This article was originally published in Scrip
Arecor, a company advancing aqueous formulation solutions for proteins, peptides and vaccines, has appointed Dr Sarah Howell chief operating officer. Dr Howell was most recently vice-president for CMC and technical development at BTG, and previously held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is an active member of the BioIndustry Association manufacturing advisory committee.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.